表紙
市場調査レポート

糖尿病性網膜症の世界市場 (2015-2019年)

Global Diabetic Retinopathy Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 306326
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
糖尿病性網膜症の世界市場 (2015-2019年) Global Diabetic Retinopathy Market 2015-2019
出版日: 2015年05月13日 ページ情報: 英文 84 Pages
概要

世界の糖尿病性網膜症の市場は2014年から2019年にかけて6.89%のCAGRで成長すると予測されています。

当レポートでは、世界の糖尿病性網膜症の治療に用いられる薬剤の市場について調査し、糖尿病性網膜症の概要、治療法、主な治療薬、分子タイプ・投薬経路・地域別の市場規模の推移と予測、薬剤開発パイプラインの動向、市場への各種影響因子の分析、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 製品概要
  • 製品プロファイル
    • Lucentis
    • Eylea

第4章 市場調査方法

第5章 イントロダクション

第6章 疾患の概要

  • 疾患について
  • 病因
  • 診断
  • 分類
  • 疫学
  • 管理
    • 抗VEGF治療
    • 眼内ステロイド注射
    • レーザー手術
    • 硝子体切除術

第7章 市場環境

  • 市場概要
  • 市場規模・予測
  • 要点
  • ファイブフォース分析

第8章 パイプラインポートフォリオ

第9章 分子タイプ別市場

  • 生物学的製剤
  • コルチコステロイド

第10章 投薬経路別市場

  • 硝子体内
  • 静脈内

第11章 地域別市場

  • 南北アメリカ
    • 市場規模・予測
  • 欧州・中東・アフリカ
    • 市場規模・予測
  • アジア太平洋
    • 市場規模・予測

第12章 購買基準

第13章 市場成長推進因子

第14章 推進因子とその影響

第15章 市場の課題

第16章 推進因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー環境

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • Novartis
    • F. Hoffmann-La Roche
    • Regeneron Pharmaceuticals
    • Bayer
  • その他の注目ベンダー

第20章 主要ベンダー分析

  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
    • 主要データ
    • 事業概要
    • 製品
    • 収益
    • 事業戦略
    • SWOT分析、など

第21章 関連レポート

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR5881

About Diabetic Retinopathy

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.

Technavio's analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market.

The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Technavio's report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

Other Prominent Vendors

  • Actavis
  • Alimera Sciences
  • Ampio Pharmaceuticals
  • Antisense Therapeutics
  • BCN Peptides
  • Boehringer Ingelheim
  • Glycadia
  • iCo Therapeutics
  • Isis Pharmaceuticals
  • Kowa Group
  • Lpath
  • Numoda Capital
  • Ohr Pharmaceutical
  • OPKO Health
  • Parexel International
  • Promedior
  • pSivida
  • Quark Pharmaceuticals
  • R-Tech Ueno
  • Sirnaomics
  • ThromboGenics

Market Driver

  • Growth in patient population
  • For a full, detailed list, view our report

Market Challenge

  • Availability of effective surgical treatments
  • For a full, detailed list, view our report

Market Trend

  • Launch of novel agents
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
  • 03.3. Product Profiles
    • 03.3.1. Lucentis
    • 03.3.2. Eylea

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology
    • 06.2.1. Elevated Blood Glucose
    • 06.2.2. Ischemia
    • 06.2.3. Hypoxia
    • 06.2.4. Neovascularization
    • 06.2.5. Increased Permeability of Retinal Vessels
  • 06.3. Diagnosis
    • 06.3.1. Retinal Photography
    • 06.3.2. Fluorescein Angiography
    • 06.3.3. Optical Coherence Tomography
  • 06.4. Classification
    • 06.4.1. Proliferative Diabetic Retinopathy
    • 06.4.2. Non-proliferative Diabetic Retinopathy
  • 06.5. Epidemiology
  • 06.6. Management
    • 06.6.1. Anti-VEGF Therapy
    • 06.6.2. Intraocular Steroid Injection
    • 06.6.3. Laser Surgery
    • 06.6.4. Vitrectomy

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Key Takeaways
  • 07.4. Five Forces Analysis

08. Pipeline Portfolio

09. Market Segmentation by Type of Molecule

  • 09.1. Biologics
  • 09.2. Corticosteroids

10. Market Segmentation by Route of Administration

  • 10.1. Intravitreal
  • 10.2. Intravenous

11. Geographical Segmentation

  • 11.1. Diabetic Retinopathy Market in Americas
    • 11.1.1. Market Size and Forecast
  • 11.2. Diabetic Retinopathy Market in EMEA
    • 11.2.1. Market Size and Forecast
  • 11.3. Diabetic Retinopathy Market in APAC
    • 11.3.1. Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Novartis
    • 19.2.2. F. Hoffmann-La Roche
    • 19.2.3. Regeneron Pharmaceuticals
    • 19.2.4. Bayer
  • 19.3. Other and Future Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Bayer
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation by Revenue 2014
    • 20.1.4. Business Segmentation by Revenue 2013 and 2014
    • 20.1.5. Geographical Segmentation by Revenue 2014
    • 20.1.6. Business Strategy
    • 20.1.7. Recent Developments
    • 20.1.8. SWOT Analysis
  • 20.2. F. Hoffmann-La Roche
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Sales by Geography
    • 20.2.6. Business Strategy
    • 20.2.7. Key Information
    • 20.2.8. SWOT Analysis
  • 20.3. Novartis
    • 20.3.1. Key Facts
    • 20.3.2. Business Description
    • 20.3.3. Business Segmentation
    • 20.3.4. Revenue by Business Segmentation
    • 20.3.5. Revenue Comparison 2012 and 2013
    • 20.3.6. Sales by Geography
    • 20.3.7. Business Strategy
    • 20.3.8. Key Developments
    • 20.3.9. SWOT Analysis
  • 20.4. Regeneron Pharmaceuticals
    • 20.4.1. Key Facts
    • 20.4.2. Business Overview
    • 20.4.3. Product Segmentation
    • 20.4.4. Revenue Product Segmentation
    • 20.4.5. Business Strategy
    • 20.4.6. Key Information
    • 20.4.7. SWOT Analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Development of Diabetic Retinopathy
  • Exhibit 3: Classification of Diabetic Retinopathy
  • Exhibit 4: Snapshot of Global Diabetic Retinopathy Market
  • Exhibit 5: Global Diabetic Retinopathy Market 2014-2019 ($ millions)
  • Exhibit 6: Key Takeaways: Global Diabetic Retinopathy Market
  • Exhibit 7: Global Diabetic Retinopathy Market by Type of Molecule
  • Exhibit 8: Segmentation of Global Diabetic Retinopathy Market by Type of Molecule 2014
  • Exhibit 9: Global Diabetic Retinopathy Market by Route of Administration
  • Exhibit 10: Segmentation of Global Diabetic Retinopathy Market by Route of Administration 2014
  • Exhibit 11: Segmentation of Global Diabetic Retinopathy Market by Geography 2014
  • Exhibit 12: Segmentation of Global Diabetic Retinopathy Market by Geography 2019
  • Exhibit 13: Diabetic Retinopathy Market in Americas 2014-2019 ($ millions)
  • Exhibit 14: Diabetic Retinopathy Market in EMEA 2014-2019 ($ millions)
  • Exhibit 15: Diabetic Retinopathy Market in APAC 2014-2019 ($ millions)
  • Exhibit 16: Major Drivers of Global Diabetic Retinopathy Market
  • Exhibit 17: Major Challenges in Global Diabetic Retinopathy Market
  • Exhibit 18: Major Trends in Global Diabetic Retinopathy Market
  • Exhibit 19: Market Share Analysis of Vendors 2014
  • Exhibit 20: Global Diabetic Retinopathy Market: Revenue by Product 2014
  • Exhibit 21: Novartis: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
  • Exhibit 22: Key Takeaways: Novartis
  • Exhibit 23: F. Hoffmann-La Roche: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
  • Exhibit 24: Key Takeaways: F. Hoffmann-La Roche
  • Exhibit 25: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate for Eylea 2011-2014 ($ millions)
  • Exhibit 26: Key Takeaways: Regeneron Pharmaceuticals
  • Exhibit 27: Bayer: YoY Revenue and Growth Rate for Eylea 2012-2014 ($ millions)
  • Exhibit 28: Key Takeaways: Bayer
  • Exhibit 29: Bayer: Business Segmentation by Revenue 2014
  • Exhibit 30: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 31: Bayer: Geographical Segmentation by Revenue 2014
  • Exhibit 32: Business Segmentation of F. Hoffmann-La Roche 2013
  • Exhibit 33: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 34: F. Hoffmann-La Roche: Pharmaceutical Sales by Geography 2013
  • Exhibit 35: F. Hoffmann-La Roche: Diagnostics Sales by Geography 2013
  • Exhibit 36: Novartis: Business Segmentation
  • Exhibit 37: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 38: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 39: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 40: Regeneron Pharmaceuticals: Product Segmentation
  • Exhibit 41: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
Back to Top